Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis
Open Access
- 5 June 2014
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 3 (6) , e29380
Abstract
Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs ...Keywords
This publication has 10 references indexed in Scilit:
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory TumorsCell, 2014
- Vascular galectins: Regulators of tumor progression and targets for cancer therapyCytokine & Growth Factor Reviews, 2013
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapyNature Medicine, 2013
- Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcomaJournal of Experimental Medicine, 2012
- Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and CancerImmunity, 2012
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Metabolism, Cell Surface Organization, and DiseaseCell, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic PerspectiveClinical Cancer Research, 2006
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971